首页>
外国专利>
Compound process peptide fragment to treat a disease in a patient in need of antioangiogenesis therapy single or double-stranded polynucleotide vector composition and process for producing a soluble kringle 5 peptide fragment or 5 kringle fusion protein
Compound process peptide fragment to treat a disease in a patient in need of antioangiogenesis therapy single or double-stranded polynucleotide vector composition and process for producing a soluble kringle 5 peptide fragment or 5 kringle fusion protein
Compounds of formulae (I) and (II), and their salts, esters and prodrugs, are new: A-B-C-X-Y (I); A-B1-C1-X1-Y (II); A = absent or a nitrogen-protecting group; Y = absent or a carboxy-protecting group; B = absent or 1-197 naturally occurring amino acids (aa) corresponding to residues 334-530 of the 791 aa human plasminogen (hPA) sequence given in the specification; C = Lys-R2-R3-Asp; R2 = Leu or Arg; R3 = Tyr, 3-iodotyrosinyl (ITyr) or Phe; X = absent or is 1-12 naturally occurring aa corresponding to residues 535-546 of hP and its homologues or analogues; B1 = absent or is 1-176 aa corresponding to residues 334-513 of hP; C1 = the 514-523 aa sequence of hP; X1 = absent or is 1-10 aa corresponding to residues 524-533 of hP.
展开▼
机译:式(I)和(II)的化合物及其盐,酯和前药是新的:A-B-C-X-Y(I); A-B1-C1-X1-Y(II); A =不存在或氮保护基; Y =不存在或羧基保护基; B =对应于说明书中给出的791aa人纤溶酶原(hPA)序列的334-530位残基的缺失或1-197个天然氨基酸(aa); C = Lys-R2-R3-Asp; R2 = Leu或Arg; R3 = Tyr,3-碘代酪氨酸(ITyr)或Phe; X =不存在或为1-12个天然存在的氨基酸,对应于hP的残基535-546及其同源物或类似物; B1 =不存在或为1-176aa,对应于hP的残基334-513; C1 = hP的514-523aa序列; X1 =不存在或为1-10aa,对应于hP的残基524-533。
展开▼